Analysts expect that Myovant Sciences Ltd (NYSE:MYOV) will report ($0.42) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Myovant Sciences’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.45). Myovant Sciences posted earnings per share of ($0.15) during the same quarter last year, which indicates a negative year over year growth rate of 180%. The company is scheduled to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Myovant Sciences will report full-year earnings of ($1.74) per share for the current fiscal year, with EPS estimates ranging from ($1.79) to ($1.68). For the next financial year, analysts anticipate that the business will report earnings of ($1.95) per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Myovant Sciences.
Several brokerages have recently commented on MYOV. JMP Securities reaffirmed an “outperform” rating and set a $25.00 price target (up previously from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Robert W. Baird reaffirmed a “buy” rating and set a $20.00 price target on shares of Myovant Sciences in a research report on Wednesday, October 4th. Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, October 3rd. Zacks Investment Research raised shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Finally, Evercore ISI began coverage on shares of Myovant Sciences in a research report on Wednesday, August 16th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $22.50.
Hedge funds have recently modified their holdings of the company. RA Capital Management LLC lifted its holdings in Myovant Sciences by 19.6% in the second quarter. RA Capital Management LLC now owns 2,807,550 shares of the company’s stock worth $32,848,000 after acquiring an additional 459,128 shares during the last quarter. Emory University bought a new position in Myovant Sciences in the second quarter worth about $1,512,000. Point72 Asset Management L.P. bought a new position in Myovant Sciences in the third quarter worth about $1,255,000. Susquehanna International Group LLP bought a new position in Myovant Sciences in the second quarter worth about $648,000. Finally, LMR Partners LLP bought a new position in Myovant Sciences in the second quarter worth about $320,000. 79.21% of the stock is currently owned by institutional investors and hedge funds.
Myovant Sciences (NYSE MYOV) traded down $0.46 during trading hours on Friday, reaching $12.07. 51,185 shares of the company’s stock were exchanged, compared to its average volume of 34,846. Myovant Sciences has a one year low of $9.92 and a one year high of $18.85.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/12/09/brokerages-expect-myovant-sciences-ltd-myov-to-announce-0-42-earnings-per-share.html.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Get a free copy of the Zacks research report on Myovant Sciences (MYOV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.